Phase ⅡStudy of Tyroserleutide for Injection in Hepatocellular Carcinoma(HCC) Patients

NCT00644020 · clinicaltrials.gov ↗

UNKNOWN

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: mitomycin, Fluorouracil

Sponsor

Shenzhen Kangzhe Pharmaceutical Co., Ltd.